USA flag logo/image

An Official Website of the United States Government

Mannan, A Potential Therapeutic for Asthma

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93912
Program Year/Program:
2009 / STTR
Agency Tracking Number:
HL090108
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CUMBERLAND PHARMACEUTICALS, INC.
CUMBERLAND PHARMACEUTICALS INC. 2525 WEST END AVE, STE 950 NASHVILLE, TN 37203
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Mannan, A Potential Therapeutic for Asthma
Agency: HHS
Contract: 1R41HL090108-01A2
Award Amount: $111,805.00
 

Abstract:

DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of benefi cial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s laboratory have shown that mannan from S. cerevisiae, a carbohydrate-based prebiotic polymannose agent, inhibits airw ay inflammation, hyperreactivity (AHR) and ASM remodeling. Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. Studies are proposed 1) to determine the optimum dose and dose timing of mannan administered intranasally. 2) to determine the optimum dose and dose timining of mannan administered orally. The University of Tennessee College of Medicine Department of Pediatric Allergy/Immunology and Cumberland Emerging Technologies Inc (CET), an affiliate of Cumberland Pharmaceuticals Inc (CPI), are collaborating to identify and develop promising pharmaceutical therapies for treating and preventing asthma. The P.I. will conduct preclinical studies outlined in the proposal and CET will develop t he product for the preclinical and clinical trials. The knowledge gained from these studies will provide a novel class of adjuctive asthma therapy that will modulate ASM remodeling and will lead to a unique intranasal and oral products that will benefit as thmatics and patients with other related diseases. PUBLIC HEALTH RELEVANCE: Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. The long-term goal of this application is to develop ma nnan derived from Baker's yeast as asthma therapy.

Principal Investigator:

Dukhee B. Lew
9015725370
DLEW@UTHSC.EDU

Business Contact:

Leo Pavliv
dkeeney@cumberlandpharma.com
Small Business Information at Submission:

CUMBERLAND PHARMACEUTICALS, INC.
CUMBERLAND PHARMACEUTICALS INC. 2525 WEST END AVE, STE 950 NASHVILLE, TN 37203

EIN/Tax ID: 621765329
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
62 S. Dunlap, Suite 300
MEMPHIS, TN 38163 6574
RI Type: Nonprofit college or university